Intellia Therapeutics (NTLA)
(Real Time Quote from BATS)
$22.32 USD
-0.55 (-2.41%)
Updated Aug 16, 2024 12:10 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 221 - 240 ( 291 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20: Broadening Footprint with In Vivo and Ex Vivo Therapies
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ahead of the ASGCT 2020 Virtual Meeting - Read Through To Our Coverage
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 20 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 13 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q19: The First Product to Enter into the Clinic in 2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
One Step Forward Two Steps Back, Downgrading to Neutral
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
In Vivo and Ex Vivo Therapies Show Encouraging Preclinical Data
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ATTR and AML Plans Are On Track With Cash Runway Through 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Is Now Entitled to the Majority Share of Worldwide ATTR Sales
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2019: Hangover: Covered Companies Roundup
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D